The falter by Forest Laboratories Inc. and Spanish partner Almirall SA in submitting a new drug application (NDA), originally planned for the first quarter of this year, pushes the duo back somewhat in the race by pharma and biotech firms to win approval of the magic potion, long-acting muscarinic antagonist with a long-acting beta agonist for chronic obstructive pulmonary disease.